CARLSBAD, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced today that its board of directors has appointed David H. Mowry as a member of the board of directors effective February 8, 2017.  Mr. Mowry will be replacing Siri S. Marshall who notified the Company that she was resigning from the Board, effective as of February 8, 2017.  Mr. Mowry is qualified as an independent director under the definition established by Nasdaq.

Mr. Mowry is President and Chief Executive Officer of Vyaire Medical, recognized global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to Vyaire Medical, Mr. Mowry held senior leadership positions within orthopedics, spine and medical device industries, including Chief Operating Officer at Wright Medical until 2016 and President and Chief Executive Officer of Tornier from 2013 to 2015. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine. Mr. Mowry intends on limiting his board participation to Alphatec (outside of Vyaire) in order to fully engage with Alphatec and remain focused on helping the Company pursue its goals.

“Dave brings a wealth of proven business and leadership experience within the orthopedic and spine industries,” said Terry Rich, Chief Executive Officer of Alphatec Spine. “Dave has been a key mentor in my career and I am excited to work with him again.  His decision to join the board demonstrates confidence in our vision and ability to build a high-growth U.S. spine company through innovation and value creation.  We look forward to his counsel and benefitting from his impressive background and expertise.”

Dave H. Mowry commented, “Alphatec is at a pivotal point in its evolution with a strong portfolio of spinal fusion products, its focus on the U.S. market and its new, spine-experienced leadership team.  I have had the pleasure of working with Terry and several of his new commercial leaders in the past.  We share a common approach for delivering results and I am excited about being engaged with him and his team.  I look forward to contributing to the achievement of their strategic goals and supporting Alphatec’s future growth.”

Mr. Mowry, age 54, has served as President and Chief Executive Officer of Vyaire Medical since May 2016. From October 2015 to May 2016 he served as Executive Vice President and Chief Operating Officer and member of the board of directors of Wright Medical Group N.V. (Nasdaq:WMGI). Between September 2015 and November 2016 he was a member of the board of directors of EndoChoice Holdings, Inc. Prior to Wright Medical, Mr. Mowry served as President and Chief Executive Officer and member of the board of directors of Tornier N.V. from February 2013 until completing the merger with Wright Medical in October 2015 and as Chief Operating Officer of Tornier from 2011 to 2013. Prior to this, Mr. Mowry held executive leadership positions at Covidien, ev3, and Zimmer Spine.  Mr. Mowry receive a B.S. in Engineering from the United States Military Academy at West Point.

Further information regarding the Company’s appointment of David H. Mowry to its board of directors is set forth in a Current Report on Form 8-K that was filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2017 and is available on both the SEC’s website at www.sec.gov and the Company’s website at www.alphatecspine.com.

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company’s mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.  Forward-looking statements include the Company’s ability to build a high-growth U.S. spine company through innovation and value creation and the Company’s ability to achieve its strategic goals.  The words “believe,” “will,” “should,” “expect,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  Please refer to the risks detailed from time to time in Alphatec Spine’s SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K.  Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com

Source: Alphatec Holdings, Inc.

Read more: http://www.nasdaq.com/press-release/alphatec-spine-announces-appointment-of-david-h-mowry-to-its-board-of-directors-20170214-00548#ixzz4YldHNmP3

RAYNHAM, Mass., Feb. 13, 2017 /PRNewswire/ — Today, DePuy Synthes*, in collaboration with LifeNet Health^®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen^® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.

ViviGen Formable contains osteoinductive, demineralized fibers that create a putty-like consistency. The fibers interconnect to achieve the formable handling favored in open void cases such as posterolateral fusion, a common type of spinal fusion surgery. This unique handling helps surgeons mold the allograft into a defined shape, allowing ViviGen Formable to conform to the surgical site.

“ViviGen Formable has a great consistency, which allows it to be packed into the openings of the posterolateral spine,” said Dr. Thomas Morrison, MD*** of Polaris Spine and Neurosurgery in Atlanta, Ga. “The handling characteristics of ViviGen Formable deliver confidence that the fusion bed is well packed and grafted for fusion.”

Both ViviGen and ViviGen Formable represent a paradigm shift in the field of bone repair by focusing on protecting viable, lineage committed bone cells from recovery to implantation while retaining all three properties required for bone formation, osteoinductivity, osteoconductivity and osteogenecity. ViviGen is now being used in a wide variety of trauma procedures for the repair or reconstruction of musculoskeletal defects.

ViviGen and ViviGen Formable are Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/Ps) comprised of cryopreserved, viable cells within a cortical cancellous bone matrix and demineralized bone. Over the past several years, LifeNet Health has conducted extensive research to enable the processing of these products to maintain cell viability, resulting in an acceptable alternative to autograft¹.

DePuy Synthes has an exclusive worldwide agreement to market and promote ViviGen and ViviGen Formable.

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its subsidiaries.
**ViviGen Formable is regulated as an HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Product); pursuant to 21 CFR 1271.
***Consultant to DePuy Synthes Spine
ViviGen and ViviGen Formable are trademarks of LifeNet Health
¹Data on File LifeNet Health DHF 12-008, DHF 15-001
DSUS/MOC/0117/0662(1) 2/17 EX-17-008

9 FEBRUARY 2017 BY MILITARY NEWS

Albany, NY — (SBWIRE) — 02/09/2017 — The Interspinous spacer market is segmented as device type, end user and geography. The product type segment is further divided in two type’s statics or compressible and dynamic or non-compressible respectively. The examples of static devices include X STOP, ExtenSure and Wallis implants. These are made up of non-compressible material such as bone, metal or synthetics. The devices produce constant amount of distraction between the spinous processes due to their non-compressible nature. Dynamic Interspinous spacer devices have a degree of compressibility. The example of dynamic devices is Coflex device formally known as Interspinous ‚U.’ it is U shaped piece of metal composed of axially compressible, which is interposed between the spinous processes. It is inserted in a compressed mode so that it exerts a distraction force between the bones. As the devices are technologically improved devices hence the market of Interspinous spacer will grow in the forecast period due to high adoption of technology in developed as well as developing countries. However, the Interspinous spacers have risk such as dislodged of implant, or sometimes requires additional surgery for the management of pain or other symptoms, which may anticipate the growth of market.

The increasing prevalence of spinal stenosis due to aging, arthritis, heredity and increased demand of surgical procedures that improved lifestyle and comfort will drive the Interspinous spacer market. The adoption of spacers are increasing due to low complication rate as compared to decompression and spinal fusion. The Interspinous spacers are widely used in geriatric population as per Medicare data due to old age patient are not comfortable with surgery due to their health conditions.

The Interspinous spacer are implanted between those vertebrae in such a way that it prevents the patient from bending too far backward which causes pain by surgical procedure. The procedure is very small and sometimes patient can go home within a day.

READ THE REST HERE

SAN DIEGO, Feb. 6, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that management will present at the Leerink Partners 6^th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on Wednesday, February 15, 2017 at 11:00 a.m. ET / 8:00 a.m. PT.

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.

About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

OR AKIVA, Israel, February 6, 2017 /PRNewswire/ —

Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, is excited to announce that Dr. Henry Ruiz of the Gadsden Regional Medical Center has been the first surgeon in Alabama to adopt the FLXfit™ articulated and lordotic expandable cage as his choice of treatment for his TLIF fusion surgeries. Dr. Henry Ruiz says that „I have used many different cages throughout my career and in the last few years I have shifted to expandable cages as I believe this technology provides great benefit to patients, especially in minimal invasive surgery”. He added that „the FLXfit expandable cage is a very unique design and different from other expandable devices I have used before and is a real game-changer in my practice”.

Dr. Ruiz notes that „many of the current expandable cages have a small surface area and expand in the weak part of the bone which can potentially enhance subsidence and compromise long term clinical outcome. The FLXfit has a very large surface area and a unique articulation mechanism which enables me to drive the cage to the front of the disc space and expand it exactly where I want it, on the strong part of the bone”. He summarizes that „I’m very excited with the FLXfit cage as it provides everything I wanted with an expandable cage in my practice, large footprint with lordotic expansion in the right location in the disc space with a very easy to use instrumentation. I’m confident that with this kind of device, I provide the best treatment for my patients”.

Ofer Bokobza, CEO of Expanding Orthopedics, says that „we are excited to collaborate with Dr. Ruiz and his team and congratulate them for joining a growing list of spine surgeons selecting the FLXfit as their new standard of care.”

About Expanding Orthopedics Inc.

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients’ outcome. The Company is spearheaded by seasoned management team, and is backed by prominent spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaim, VP Marketing and Sales
E-mail: david@xortho.com
Phone: +1-(347)-3219683

SOURCE Expanding Orthopedics Inc. (EOI)

February 02, 2017

CHESTERFIELD, Mo.–(EON: Enhanced Online News)–SpineSource, Inc. has entered into a long term exclusive distribution agreement with Kisco International to market, sell and distribute Kisco’s L-Varlock^® Expandable Lumbar Cage for vertebral interbody fusion in the United States.

The L-Varlock^® Expandable Lumbar Cage provides spine surgeons a device which can be expanded from any range of zero to 24.5° of angle, and from zero to 7.1 mm of expansion within the disc space. Made of titanium alloy, it provides a preferred material for bony osteointegration and a wide open framework for bony in-growth.

“Bone-healing principles never change and the simplicity of this device provides surgeons the ability to follow the fundamental principles of sagittal balance, re-establishment of disc height, and the provision of a large fusion bed within and around the implanted cage,” said Tom Mitchell, President and CEO of SpineSource. “With the adjunct of supplemental fixation, the L-Varlock® Expandable Cage puts the odds in favor of the surgeon and patient to achieve the goal of segmental stability, proper angles, and fusion.”

“What we have seen from our initial launch in 2016 is that surgeons like the simplicity of the expansion, a tactile feel while expanding, and the ability to pack copious amounts of autograft before and after expansion,” added Mr. Mitchell.

SpineSource will market and distribute the L-Varlock® Expandable Cage through its independent sales force which exceeds more than 750 independent professional spinal implant sales professionals nationwide.

SpineSource was founded in 2004, becoming the exclusive distributor for Ulrich Medical GmbH and then was a founder of Ulrich Medical USA in 2007, still based in St. Louis County. In 2008, SpineSource launched expandable PEEK cages from Advanced Medical Technologies, AG which was acquired by Medtronic in 2012.

The Mission of SpineSource is to provide the highest level of quality service based upon clinical and industry expertise and ethics while delivering intelligent technology promoting the well-being of patients with spinal disorders.